Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 82, Issue 4, Pages 448-452Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.clpt.6100321
Keywords
-
Categories
Funding
- Medical Research Council [G0300496, G0300273] Funding Source: researchfish
- MRC [G0300496, G0300273] Funding Source: UKRI
- Medical Research Council [G0300273, G0300496] Funding Source: Medline
Ask authors/readers for more resources
The potential of somatic cell therapies from human embryonic stem cells ( hESCs) as alternatives to traditional drug-based remedies for treating some of mankind's most debilitating diseases has resulted in the need to translate rapidly proof-of-principle and basic research into clinical application. Consequently, researchers and regulatory bodies are now facing one of the major obstacles of the field: the efficient and reproducible generation of clinical-grade cells suitable for producing therapeutic cell types to administer to patients in phase-I and phase-II clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available